Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: HD 1916, HD-1916, chemically synthesized semaglutide, semaglutide injection (HD1916)
HD1916 is identified in the clinical literature as chemically synthesized semaglutide. Semaglutide is a 31-amino-acid GLP-1 analogue with albumin-binding and DPP-4-stabilizing structural modifications. HD1916 was evaluated as a once-weekly subcutaneous preparation in a phase III obesity study against reference semaglutide.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
In the phase III study, adults with obesity received once-weekly subcutaneous HD1916 for 44 weeks, with dose escalation through 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg levels as recorded in the trial registry. These are study-regimen levels and are not presented as catalog package sizes or individualized dosing guidance. HD1916-specific formulation composition, excipients, concentration, storage conditions, sequence-level distinctions from semaglutide, and independent pharmacokinetic characterization were not reliably established from the authoritative sources reviewed.
Supplementary research context only. Not medical advice or a treatment recommendation.
HD1916-specific chemical identifiers were not located in the authoritative sources reviewed. Parent compound semaglutide: CAS 910463-68-2; PubChem CID 56843331; molecular formula C187H291N45O59; molecular weight 4113.58 g/mol.
HD1916 appears to be a development or product code for a chemically synthesized semaglutide preparation rather than a distinct semaglutide analogue with a separately characterized molecular identity. The cited phase III publication reported HD1916 as therapeutically equivalent to reference semaglutide for body-weight reduction over 44 weeks in adults with obesity without diabetes; the study was funded by CSPC Baike and included company-affiliated authors.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention HD1916 or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.